Published in Nat Clin Pract Neurol on November 01, 2008
Rotenone, paraquat, and Parkinson's disease. Environ Health Perspect (2011) 3.87
PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med (2010) 3.48
Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. EMBO J (2012) 2.36
Ubiquitination in postsynaptic function and plasticity. Annu Rev Cell Dev Biol (2010) 1.94
L-type calcium channel blockers and Parkinson disease in Denmark. Ann Neurol (2010) 1.86
A neo-substrate that amplifies catalytic activity of parkinson's-disease-related kinase PINK1. Cell (2013) 1.84
Diabetes and risk of Parkinson's disease. Diabetes Care (2011) 1.80
Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease. Free Radic Biol Med (2012) 1.67
LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. Hum Mol Genet (2012) 1.56
Abnormal mitochondrial dynamics and neurodegenerative diseases. Biochim Biophys Acta (2009) 1.49
Potential therapeutic benefits of strategies directed to mitochondria. Antioxid Redox Signal (2010) 1.40
Calcium homeostasis, selective vulnerability and Parkinson's disease. Trends Neurosci (2009) 1.34
Parkinson's disease and α-synuclein expression. Mov Disord (2011) 1.34
Calcium, cellular aging, and selective neuronal vulnerability in Parkinson's disease. Cell Calcium (2010) 1.34
Mutant A53T alpha-synuclein induces neuronal death by increasing mitochondrial autophagy. J Biol Chem (2011) 1.33
Nutraceutical antioxidants as novel neuroprotective agents. Molecules (2010) 1.29
Recent advances in our understanding of neurodegeneration. J Neural Transm (Vienna) (2009) 1.27
Regulation of mitochondrial respiratory chain biogenesis by estrogens/estrogen receptors and physiological, pathological and pharmacological implications. Biochim Biophys Acta (2009) 1.26
Metabolic rescue in pluripotent cells from patients with mtDNA disease. Nature (2015) 1.23
The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson's disease. Neuroscience (2011) 1.20
Oxidative stress in Niemann-Pick disease, type C. Mol Genet Metab (2010) 1.18
Mitochondria as a therapeutic target for aging and neurodegenerative diseases. Curr Alzheimer Res (2011) 1.17
Stimulation of the rat subthalamic nucleus is neuroprotective following significant nigral dopamine neuron loss. Neurobiol Dis (2010) 1.14
Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One (2013) 1.12
cAMP/PKA signaling balances respiratory activity with mitochondria dependent apoptosis via transcriptional regulation. BMC Cell Biol (2010) 1.11
LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson's disease patients: reversal by gene correction. Neurobiol Dis (2013) 1.10
Statin use and the risk of Parkinson disease. Neurology (2008) 1.10
DLP1-dependent mitochondrial fragmentation mediates 1-methyl-4-phenylpyridinium toxicity in neurons: implications for Parkinson's disease. Aging Cell (2011) 1.09
Tickled PINK1: mitochondrial homeostasis and autophagy in recessive Parkinsonism. Biochim Biophys Acta (2009) 1.09
Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders. Am J Neurodegener Dis (2013) 1.08
3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of central nervous system diseases. Arch Neurol (2010) 1.08
Oxidation of the cysteine-rich regions of parkin perturbs its E3 ligase activity and contributes to protein aggregation. Mol Neurodegener (2011) 1.05
Mitochondrial abnormalities in temporal lobe of autistic brain. Neurobiol Dis (2013) 1.04
Mitophagy programs: mechanisms and physiological implications of mitochondrial targeting by autophagy. Cell Mol Life Sci (2015) 1.03
Coenzyme Q10 effects in neurodegenerative disease. Neuropsychiatr Dis Treat (2009) 1.01
Mitochondrial dysfunction and the pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Int J Clin Exp Med (2012) 1.01
Mitochondrial DNA damage: molecular marker of vulnerable nigral neurons in Parkinson's disease. Neurobiol Dis (2014) 1.00
α-Synuclein and mitochondrial bioenergetics regulate tetrahydrobiopterin levels in a human dopaminergic model of Parkinson disease. Free Radic Biol Med (2013) 0.99
Dynamic O-GlcNAcylation and its roles in the cellular stress response and homeostasis. Cell Stress Chaperones (2013) 0.98
Oxidative stress in genetic mouse models of Parkinson's disease. Oxid Med Cell Longev (2012) 0.98
Parkinson's disease: Mitochondrial damage control. Nature (2010) 0.97
Parkinson's disease brain mitochondria have impaired respirasome assembly, age-related increases in distribution of oxidative damage to mtDNA and no differences in heteroplasmic mtDNA mutation abundance. Mol Neurodegener (2009) 0.97
Lipid pathway alterations in Parkinson's disease primary visual cortex. PLoS One (2011) 0.96
Crosstalk between JNK and SUMO signaling pathways: deSUMOylation is protective against H2O2-induced cell injury. PLoS One (2011) 0.96
PINK1 and Parkin control localized translation of respiratory chain component mRNAs on mitochondria outer membrane. Cell Metab (2015) 0.96
Identification and characterization of a leucine-rich repeat kinase 2 (LRRK2) consensus phosphorylation motif. PLoS One (2010) 0.96
Outdoor work and risk for Parkinson's disease: a population-based case-control study. Occup Environ Med (2010) 0.95
The many roads to mitochondrial dysfunction in neuroimmune and neuropsychiatric disorders. BMC Med (2015) 0.94
Endoplasmic reticulum stress in skeletal muscle homeostasis and disease. Curr Rheumatol Rep (2012) 0.94
Nonimmune mechanisms of muscle damage in myositis: role of the endoplasmic reticulum stress response and autophagy in the disease pathogenesis. Curr Opin Rheumatol (2009) 0.94
Oxidative damage to RNA but not DNA in the hippocampus of patients with major mental illness. J Psychiatry Neurosci (2010) 0.93
Oxidized DJ-1 interacts with the mitochondrial protein BCL-XL. J Biol Chem (2011) 0.93
Statin use and Parkinson's disease in Denmark. Mov Disord (2010) 0.93
Associations between Vitamin D Status, Supplementation, Outdoor Work and Risk of Parkinson's Disease: A Meta-Analysis Assessment. Nutrients (2015) 0.92
Antioxidant gene therapy against neuronal cell death. Pharmacol Ther (2013) 0.92
Mitochondria in neurodegenerative disorders: regulation of the redox state and death signaling leading to neuronal death and survival. J Neural Transm (Vienna) (2009) 0.92
Compartmentalized cancer drug discovery targeting mitochondrial Hsp90 chaperones. Oncogene (2009) 0.92
Dopaminergic neurotoxicant 6-OHDA induces oxidative damage through proteolytic activation of PKCδ in cell culture and animal models of Parkinson's disease. Toxicol Appl Pharmacol (2011) 0.92
Genetic modification of the association of paraquat and Parkinson's disease. Mov Disord (2012) 0.91
Early Expression of Parkinson's Disease-Related Mitochondrial Abnormalities in PINK1 Knockout Rats. Mol Neurobiol (2014) 0.90
Hyperexcitable substantia nigra dopamine neurons in PINK1- and HtrA2/Omi-deficient mice. J Neurophysiol (2010) 0.90
Mitochondrial dysfunction in genetic animal models of Parkinson's disease. Antioxid Redox Signal (2011) 0.90
Synthesis and neuroprotective action of xyloketal derivatives in Parkinson's disease models. Mar Drugs (2013) 0.90
Neuroprotective effects of a variety of pomegranate juice extracts against MPTP-induced cytotoxicity and oxidative stress in human primary neurons. Oxid Med Cell Longev (2013) 0.90
Characterization of cellular protective effects of ATP13A2/PARK9 expression and alterations resulting from pathogenic mutants. J Neurosci Res (2012) 0.89
Mitochondrial alterations by PARKIN in dopaminergic neurons using PARK2 patient-specific and PARK2 knockout isogenic iPSC lines. Stem Cell Reports (2015) 0.89
Cutting edge: IL-13Rα1 expression in dopaminergic neurons contributes to their oxidative stress-mediated loss following chronic peripheral treatment with lipopolysaccharide. J Immunol (2012) 0.89
A water soluble CoQ10 formulation improves intracellular distribution and promotes mitochondrial respiration in cultured cells. PLoS One (2012) 0.89
Protective effects of PEP-1-Catalase on stress-induced cellular toxicity and MPTP-induced Parkinson's disease. BMB Rep (2015) 0.89
Mitochondrial Dysfunction in Parkinson's Disease. Exp Neurobiol (2015) 0.88
Autophagy inhibitor LRPPRC suppresses mitophagy through interaction with mitophagy initiator Parkin. PLoS One (2014) 0.88
Quantitation of hydrogen peroxide fluctuations and their modulation of dopamine dynamics in the rat dorsal striatum using fast-scan cyclic voltammetry. ACS Chem Neurosci (2013) 0.88
Thiol-redox signaling, dopaminergic cell death, and Parkinson's disease. Antioxid Redox Signal (2012) 0.88
Genetic variation of the mitochondrial complex I subunit NDUFV2 and Parkinson's disease. Parkinsonism Relat Disord (2010) 0.88
Role of oxidative stress in refractory epilepsy: evidence in patients and experimental models. Int J Mol Sci (2013) 0.87
Coenzyme q10 therapy. Mol Syndromol (2014) 0.87
Neuroprotective effect of thymoquinone, the nigella sativa bioactive compound, in 6-hydroxydopamine-induced hemi-parkinsonian rat model. Iran J Pharm Res (2014) 0.86
Human adipose tissue-derived multilineage progenitor cells exposed to oxidative stress induce neurite outgrowth in PC12 cells through p38 MAPK signaling. BMC Cell Biol (2012) 0.86
Mitochondrial dynamics regulate growth cone motility, guidance, and neurite growth rate in perinatal retinal ganglion cells in vitro. Invest Ophthalmol Vis Sci (2012) 0.86
The G2019S pathogenic mutation disrupts sensitivity of leucine-rich repeat kinase 2 to manganese kinase inhibition. J Neurochem (2010) 0.86
Parkinson's disease-like neuromuscular defects occur in prenyl diphosphate synthase subunit 2 (Pdss2) mutant mice. Mitochondrion (2011) 0.85
Human SOD2 modification by dopamine quinones affects enzymatic activity by promoting its aggregation: possible implications for Parkinson's disease. PLoS One (2012) 0.85
Mitochondria: A Therapeutic Target for Parkinson's Disease? Int J Mol Sci (2015) 0.85
Glutaredoxin 1 protects dopaminergic cells by increased protein glutathionylation in experimental Parkinson's disease. Antioxid Redox Signal (2012) 0.85
Extension of Drosophila lifespan by Rosa damascena associated with an increased sensitivity to heat. Biogerontology (2011) 0.85
PINK1 and Parkin to control mitochondria remodeling. Anat Cell Biol (2010) 0.84
Mitochondrial glutathione transport is a key determinant of neuronal susceptibility to oxidative and nitrosative stress. J Biol Chem (2013) 0.84
Proanthocyanidin-rich fraction from Croton celtidifolius Baill confers neuroprotection in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine rat model of Parkinson's disease. J Neural Transm (Vienna) (2010) 0.84
Hydrogen peroxide responsive miR153 targets Nrf2/ARE cytoprotection in paraquat induced dopaminergic neurotoxicity. Toxicol Lett (2014) 0.84
Regional skeletal muscle remodeling and mitochondrial dysfunction in right ventricular heart failure. Am J Physiol Heart Circ Physiol (2011) 0.84
Activation of transcription factor MEF2D by bis(3)-cognitin protects dopaminergic neurons and ameliorates Parkinsonian motor defects. J Biol Chem (2012) 0.83
Potent organo-osmium compound shifts metabolism in epithelial ovarian cancer cells. Proc Natl Acad Sci U S A (2015) 0.83
One-step generation of triple gene-targeted pigs using CRISPR/Cas9 system. Sci Rep (2016) 0.83
Dynamics of Human Mitochondrial Complex I Assembly: Implications for Neurodegenerative Diseases. Front Mol Biosci (2016) 0.83
Rhythmic oscillations of the microRNA miR-96-5p play a neuroprotective role by indirectly regulating glutathione levels. Nat Commun (2014) 0.83
Fine mapping of gene regions regulating neurodegeneration. PLoS One (2009) 0.83
Dopamine neuron stimulating actions of a GDNF propeptide. PLoS One (2010) 0.83
LC/MS characterization of rotenone induced cardiolipin oxidation in human lymphocytes: implications for mitochondrial dysfunction associated with Parkinson's disease. Mol Nutr Food Res (2013) 0.83
Mitochondrial dysfunction of immortalized human adipose tissue-derived mesenchymal stromal cells from patients with Parkinson's disease. Exp Neurobiol (2013) 0.82
Green tea polyphenols extend the lifespan of male drosophila melanogaster while impairing reproductive fitness. J Med Food (2014) 0.82
Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature (2006) 15.69
Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature (2011) 7.90
Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nat Med (2006) 7.21
Reduced-median-network analysis of complete mitochondrial DNA coding-region sequences for the major African, Asian, and European haplogroups. Am J Hum Genet (2002) 6.02
Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc Natl Acad Sci U S A (2006) 5.78
Pink1 regulates mitochondrial dynamics through interaction with the fission/fusion machinery. Proc Natl Acad Sci U S A (2008) 4.97
Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol (2002) 4.60
Parkinson's disease. Hum Mol Genet (2007) 3.84
Neural subtype specification of fertilization and nuclear transfer embryonic stem cells and application in parkinsonian mice. Nat Biotechnol (2003) 3.43
Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice. J Exp Med (2009) 3.32
Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci (2009) 3.24
Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol (2002) 3.23
Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron (2003) 2.80
Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. Proc Natl Acad Sci U S A (2004) 2.77
Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol Med (2008) 2.74
Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice. J Biol Chem (2002) 2.68
Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling. Proc Natl Acad Sci U S A (2005) 2.58
Mitochondrial alpha-ketoglutarate dehydrogenase complex generates reactive oxygen species. J Neurosci (2004) 2.57
Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol (2009) 2.46
Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J Biol Chem (2004) 2.43
Somatic mitochondrial DNA mutations in early Parkinson and incidental Lewy body disease. Ann Neurol (2012) 2.08
Lipid peroxidation in aging brain and Alzheimer's disease. Free Radic Biol Med (2002) 2.08
Sensitivity to oxidative stress in DJ-1-deficient dopamine neurons: an ES- derived cell model of primary Parkinsonism. PLoS Biol (2004) 2.02
Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J Neurosci (2002) 2.01
Mitochondrial dysfunction and amyotrophic lateral sclerosis. Muscle Nerve (2006) 1.95
Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One (2011) 1.93
Therapeutic effects of cystamine in a murine model of Huntington's disease. J Neurosci (2002) 1.92
Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease. Free Radic Biol Med (2010) 1.91
Resveratrol protects against peripheral deficits in a mouse model of Huntington's disease. Exp Neurol (2010) 1.91
Impaired mitochondrial function in psychiatric disorders. Nat Rev Neurosci (2012) 1.80
The energetics of Huntington's disease. Neurochem Res (2004) 1.79
Mutant superoxide dismutase 1 forms aggregates in the brain mitochondrial matrix of amyotrophic lateral sclerosis mice. J Neurosci (2005) 1.79
Oxidative damage in Huntington's disease pathogenesis. Antioxid Redox Signal (2006) 1.79
Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochem Int (2008) 1.76
High aggregate burden of somatic mtDNA point mutations in aging and Alzheimer's disease brain. Hum Mol Genet (2002) 1.75
Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration. J Neurosci (2007) 1.66
Impaired PGC-1alpha function in muscle in Huntington's disease. Hum Mol Genet (2009) 1.63
Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents. Curr Drug Targets CNS Neurol Disord (2005) 1.62
Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease. Hum Mol Genet (2010) 1.62
Inhibition of the leucine-rich repeat protein LINGO-1 enhances survival, structure, and function of dopaminergic neurons in Parkinson's disease models. Proc Natl Acad Sci U S A (2007) 1.58
Neuroprotective strategies involving ROS in Alzheimer disease. Free Radic Biol Med (2010) 1.57
Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease. J Neurosci (2004) 1.54
The role of mitochondria in inherited neurodegenerative diseases. J Neurochem (2006) 1.53
Uncoupling protein 2 prevents neuronal death including that occurring during seizures: a mechanism for preconditioning. Endocrinology (2003) 1.50
Mitochondrial approaches for neuroprotection. Ann N Y Acad Sci (2008) 1.48
Reduction of oxidative stress, amyloid deposition, and memory deficit by manganese superoxide dismutase overexpression in a transgenic mouse model of Alzheimer's disease. FASEB J (2009) 1.47
Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp Neurol (2005) 1.46
Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol Dis (2005) 1.46
Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Muscle Nerve (2007) 1.45
Behavioral deficits and progressive neuropathology in progranulin-deficient mice: a mouse model of frontotemporal dementia. FASEB J (2010) 1.44
Matrix metalloproteinase-3: a novel signaling proteinase from apoptotic neuronal cells that activates microglia. J Neurosci (2005) 1.44
Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease. Hum Mol Genet (2011) 1.44
Celastrol protects against MPTP- and 3-nitropropionic acid-induced neurotoxicity. J Neurochem (2005) 1.44
Are mitochondria critical in the pathogenesis of Alzheimer's disease? Brain Res Brain Res Rev (2005) 1.43
Mitochondrial DNA and respiratory chain function in spinal cords of ALS patients. J Neurochem (2002) 1.42
PGC-1alpha, a new therapeutic target in Huntington's disease? Cell (2006) 1.42
Protection from Alzheimer's-like disease in the mouse by genetic ablation of inducible nitric oxide synthase. J Exp Med (2005) 1.40
Somatic mitochondrial DNA mutations in single neurons and glia. Neurobiol Aging (2004) 1.37
Unexpected lack of hypersensitivity in LRRK2 knock-out mice to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine). J Neurosci (2009) 1.36
Somatic mitochondrial DNA mutations in cortex and substantia nigra in aging and Parkinson's disease. Neurobiol Aging (2004) 1.36
Alzheimer's APP mangles mitochondria. Nat Med (2006) 1.36
Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis. Biochim Biophys Acta (2008) 1.35
Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci (2006) 1.34
Mitochondrial dysfunction in neurodegenerative diseases. J Pharmacol Exp Ther (2012) 1.33
Cause and consequence: mitochondrial dysfunction initiates and propagates neuronal dysfunction, neuronal death and behavioral abnormalities in age-associated neurodegenerative diseases. Biochim Biophys Acta (2009) 1.33
Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice. Brain Res (2003) 1.32
The role of NADPH oxidase 1-derived reactive oxygen species in paraquat-mediated dopaminergic cell death. Antioxid Redox Signal (2009) 1.31
Metabolomic analysis and signatures in motor neuron disease. Metabolomics (2005) 1.31
Mice lacking alpha-synuclein are resistant to mitochondrial toxins. Neurobiol Dis (2005) 1.30
PINK1 defect causes mitochondrial dysfunction, proteasomal deficit and alpha-synuclein aggregation in cell culture models of Parkinson's disease. PLoS One (2009) 1.30
Autophagy in neurodegenerative disorders: pathogenic roles and therapeutic implications. Trends Neurosci (2010) 1.30
Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription. PLoS One (2009) 1.29
Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease. EMBO Mol Med (2010) 1.27
Cell-permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis. J Neurochem (2006) 1.26
Manganese porphyrin given at symptom onset markedly extends survival of ALS mice. Ann Neurol (2005) 1.25
Thiamine deficiency induces oxidative stress and exacerbates the plaque pathology in Alzheimer's mouse model. Neurobiol Aging (2008) 1.24
The alpha-ketoglutarate-dehydrogenase complex: a mediator between mitochondria and oxidative stress in neurodegeneration. Mol Neurobiol (2005) 1.23
Celastrol blocks neuronal cell death and extends life in transgenic mouse model of amyotrophic lateral sclerosis. Neurodegener Dis (2005) 1.23
Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases. J Neurochem (2009) 1.22
A pivotal role of matrix metalloproteinase-3 activity in dopaminergic neuronal degeneration via microglial activation. FASEB J (2006) 1.22
Mitochondria targeted peptides protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Antioxid Redox Signal (2009) 1.20
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. J Neurochem (2003) 1.20
Clinically approved heterocyclics act on a mitochondrial target and reduce stroke-induced pathology. J Exp Med (2004) 1.19
Metabolomic profiling in LRRK2-related Parkinson's disease. PLoS One (2009) 1.19
Mice deficient in dihydrolipoamide dehydrogenase show increased vulnerability to MPTP, malonate and 3-nitropropionic acid neurotoxicity. J Neurochem (2004) 1.19
Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem (2004) 1.17
Does the mitochondrial genome play a role in the etiology of Alzheimer's disease? Hum Genet (2006) 1.16
MicroRNA-related cofilin abnormality in Alzheimer's disease. PLoS One (2010) 1.15
Bioenergetic abnormalities in discrete cerebral motor pathways presage spinal cord pathology in the G93A SOD1 mouse model of ALS. Neurobiol Dis (2006) 1.15
Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation. Hum Mol Genet (2010) 1.14
Expression of MMP-2, MMP-9, and MMP-1 and their endogenous counterregulators TIMP-1 and TIMP-2 in postmortem brain tissue of Parkinson's disease. Exp Neurol (2002) 1.13
Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease. Neurochem Int (2003) 1.13
Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis. Free Radic Biol Med (2011) 1.13
Minocycline enhances MPTP toxicity to dopaminergic neurons. J Neurosci Res (2003) 1.13
Nitration of Hsp90 induces cell death. Proc Natl Acad Sci U S A (2013) 1.13
A role of mitochondrial complex II defects in genetic models of Huntington's disease expressing N-terminal fragments of mutant huntingtin. Hum Mol Genet (2013) 1.13
NADPH oxidase 1-mediated oxidative stress leads to dopamine neuron death in Parkinson's disease. Antioxid Redox Signal (2012) 1.12
Treatment with a catalytic antioxidant corrects the neurobehavioral defect in ataxia-telangiectasia mice. Free Radic Biol Med (2004) 1.12
Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism. J Neurochem (2007) 1.10